

ASSOCIATIONS OF FGF-23 AND KLOTHO SERUM LEVELS WITH CARDIOVASCULAR RISK IN CHRONIC KIDNEY DISEASE PATIENTS

Authors: Dudareva A.V., Brovko M.Y., Milovanova L.Y. [contact - Ludm.milovanova@gmail.com](mailto:Ludm.milovanova@gmail.com)

Institution: I.M. Sechenov First Moscow State Medical University, Clinic of Nephrology, Internal and Occupational diseases, Russia

OBJECTIVES: was to identify the role of serum FGF-23 and Klotho as cardiovascular risk markers in CKD stage 1- 5D.

METHODS: The main group consisted of 130 CKD patients (67m / 63f, 20-65 yrs, average age $41 \pm 6,7$ years) Control group: 30 healthy volunteers matched by age and sex. All patients were observed in dynamic within 1 year. ELISA was used for serum FGF-23 and Klotho.

RESULTS: Dynamic of serum Klotho and FGF-23, when compared to serum phosphate and PTH, resulted in its changed already from stage 3A of CKD whereas PTH and phosphorus - only from stage 4-5 (Fig.1).

We found also a negative relation between serum Klotho levels and pulse wave velocity (PWV) [$r=-0,647; p<0,01$]. Between increased level of FGF-23 and PWV a positive correlation was found (Fig.2).




Fig.2

Among the studied factors FGF-23 serum levels were strongly correlated with the myocardial remodeling (Fig.4).





Fig.4

According to the ROC-analysis, the values of serum Klotho below 487 pg/ml testified the PWV increasing with 80% sensitivity and 75% specificity (Fig.6)

Klotho- marker of cardiovascular protection in CKD patients



	AUC-area under the curve	The sensitivity / specificity
Klotho	0,83	<487 pg/ml – 80 %/ 75%

Fig.6

CONCLUSION: Besides the important role of FGF-23, Klotho in mineral metabolism in CKD their pleiotropic effects associated with cardiovascular complications are becoming more apparent. Based on the obtained results, serum FGF-23 and Klotho should be considered as early markers of cardiovascular risk in patients with CKD.




Fig.1

A significant negative relation between serum Klotho levels and the degree of heart calcification [$r=-0,612; p<0,01$] assessed by semiquantitative scale was obtained. Between FGF-23 serum levels and the degree of calcification positive correlation was found [$r=0,498; p<0,05$] (Fig.3).




Fig.3

According to the multiple regression analysis, left ventricular mass index was higher in patients with higher serum FGF-23, phosphate, central systolic blood pressure (BP) and pulse wave velocity (PWV). According to the ROC-analysis, the value of serum FGF-23 above 412 pg / ml, testified Left Ventricular Hypertrophy with 80% sensitivity and 76% specificity (Fig.5).


FGF-23 - marker of cardiac damage in CKD

Multiple regression analysis

$$LVMMI = 18,4 \times FGF-23 + 12,4 \times P + 0,35 \times SBP + 64,3 \times PWV - 7,52$$

($R^2 = 0,36; F=36,9; p < 0,001$)

ROC-analysis



	AUC-area under the curve	The sensitivity / specificity
FGF-23	0,76	>412pg/ml – 80 %/ 76%

Fig.5

REFERENCE: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evolution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int.* 2009; 76 (Suppl.113): 1-130.

This work was supported by the Russian Science Foundation (grant № 14-15-00947 2014)